The Growth Hormone Secretagogues and Epilepsia
A special issue of Journal of Personalized Medicine (ISSN 2075-4426).
Deadline for manuscript submissions: closed (25 July 2022) | Viewed by 2452
Special Issue Editors
Interests: neuropeptides; epilepsy; GHS; neurodegenerative diseases
Special Issue Information
Dear Colleagues,
This Special Issue of the Journal of Personalized Medicine welcomes manuscripts focusing on the most recent advances in mechanisms involved in epileptogenesis, as well as on the possible innovative treatments. In recent years, the neuropeptide ghrelin and its synthetic analogues (GHSs) have emerged as promising candidates in the field of epilepsy. Human studies have shown increased or decreased levels of ghrelin in patients with epilepsy. The effects of ghrelin are usually suggested to be mediated by its action on the GHSR1a, but some studies have already indicated the possibility that ghrelin’s neuroprotective effects could be independent of the GHSR1a. The GHSs have great clinical potential in the field of epilepsy, and a better understanding of their mechanism of anticonvulsant action could promote the development of novel synthetic analogs with clinical potential in epilepsy.
Dr. Antonio Torsello
Dr. Robert J. Omeljaniuk
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ghrelin
- hexarelin
- GHS
- epilepsy
- translational research
- prevention and treatment
- personalized medicine
- clinical studies
- preclinical models